

Paul N Span

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3320115/publications.pdf>

Version: 2024-02-01

248
papers

26,843
citations

22153

59
h-index

6836

155
g-index

258
all docs

258
docs citations

258
times ranked

49502
citing authors

#	ARTICLE	IF	CITATIONS
1	Production of 11-Oxygenated Androgens by Testicular Adrenal Rest Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e272-e280.	3.6	12
2	Diurnal salivary androstenedione and 17 α -hydroxyprogesterone levels in healthy volunteers for monitoring treatment efficacy of patients with congenital adrenal hyperplasia. <i>Clinical Endocrinology</i> , 2022, 97, 36-42.	2.4	8
3	Abstract P3-09-18: The association between genomic alterations and body mass index in patients with early breast cancer. <i>Cancer Research</i> , 2022, 82, P3-09-18-P3-09-18.	0.9	0
4	Optimizing the Timing of Highest Hydrocortisone Dose in Children and Adolescents With 21-Hydroxylase Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1661-e1672.	3.6	5
5	Tunable Hybrid Matrices Drive Epithelial Morphogenesis and YAP Translocation. <i>Advanced Science</i> , 2021, 8, 2003380.	11.2	13
6	Genotyping and Characterization of HPV Status, Hypoxia, and Radiosensitivity in 22 Head and Neck Cancer Cell Lines. <i>Cancers</i> , 2021, 13, 1069.	3.7	5
7	Letter to the editor: Hypoxia kinetics and histology in combined radiotherapy and oxidative phosphorylation inhibition effects on antitumor immunity. , 2021, 9, e001793.		1
8	Quality of Life in Men With Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. <i>Frontiers in Endocrinology</i> , 2021, 12, 626646.	3.5	8
9	Radiotherapy and cGAS/STING signaling: Impact on MDSCs in the tumor microenvironment. <i>Cellular Immunology</i> , 2021, 362, 104298.	3.0	35
10	Improving Breast Cancer Treatment Specificity Using Aptamers Obtained by 3D Cell-SELEX. <i>Pharmaceuticals</i> , 2021, 14, 349.	3.8	16
11	Production of 11-Oxygenated Androgens by Testicular Adrenal Rest Tumors. <i>Journal of the Endocrine Society</i> , 2021, 5, A814-A815.	0.2	0
12	Targeting Oxidative Phosphorylation to Increase the Efficacy of Radio- and Immune-Combination Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 2970-2978.	7.0	44
13	P120 and E-cadherin: Double-edged swords in tumor metastasis. <i>Seminars in Cancer Biology</i> , 2020, 60, 107-120.	9.6	67
14	Polyisocyanide Hydrogels as a Tunable Platform for Mammary Gland Organoid Formation. <i>Advanced Science</i> , 2020, 7, 2001797.	11.2	31
15	Prognostic significance of VEGF and components of the plasminogen activator system in endometrial cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1725-1735.	2.5	6
16	AKT inhibition as a strategy for targeting hypoxic HPV-positive HNSCC. <i>Radiotherapy and Oncology</i> , 2020, 149, 1-7.	0.6	7
17	Editorial: Advances in Biological Understanding of Tumor Radiation Resistance. <i>Frontiers in Oncology</i> , 2020, 10, 754.	2.8	2
18	Changes in DNA Damage Repair Gene Expression and Cell Cycle Gene Expression Do Not Explain Radioresistance in Tamoxifen-Resistant Breast Cancer. <i>Oncology Research</i> , 2020, 28, 33-40.	1.5	12

#	ARTICLE	IF	CITATIONS
19	The tumor microenvironment and radiotherapy response; a central role for cancer-associated fibroblasts. <i>Clinical and Translational Radiation Oncology</i> , 2020, 22, 90-97.	1.7	64
20	Collective invasion induced by an autocrine purinergic loop through connexin-43 hemichannels. <i>Journal of Cell Biology</i> , 2020, 219, .	5.2	21
21	Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B. <i>ELife</i> , 2020, 9, .	6.0	25
22	Abstract 286: Regulation of APOBEC3B gene expression through the Rb/E2F pathway. , 2020, , .		0
23	HPV, hypoxia and radiation response in head and neck cancer. <i>British Journal of Radiology</i> , 2019, 92, 20180047.	2.2	44
24	Isocitrate dehydrogenase 1-mutated human gliomas depend on lactate and glutamate to alleviate metabolic stress. <i>FASEB Journal</i> , 2019, 33, 557-571.	0.5	33
25	Downregulation of matrix Gla protein is a biomarker for tamoxifen-resistant and radioresistant breast cancer. <i>Biomarkers in Medicine</i> , 2019, 13, 841-850.	1.4	3
26	HER2, chromosome 17 polysomy and DNA ploidy status in breast cancer; a translational study. <i>Scientific Reports</i> , 2019, 9, 11679.	3.3	15
27	Inhibition of CDK4/CDK6 Enhances Radiosensitivity of HPV Negative Head and Neck Squamous Cell Carcinomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 548-558.	0.8	37
28	The Role of Hypoxia and the Immune System in Tumor Radioresistance. <i>Cancers</i> , 2019, 11, 1555.	3.7	8
29	Glucose and glutamine metabolism in relation to mutational status in NSCLC histological subtypes. <i>Thoracic Cancer</i> , 2019, 10, 2289-2299.	1.9	20
30	Glucocorticoid Activity of Adrenal Steroid Precursors in Untreated Patients With Congenital Adrenal Hyperplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5065-5072.	3.6	26
31	P120 Catenin Isoforms Differentially Associate with Breast Cancer Invasion and Metastasis. <i>Cancers</i> , 2019, 11, 1459.	3.7	11
32	Differential expression of p120-catenin 1 and 3 isoforms in epithelial tissues. <i>Scientific Reports</i> , 2019, 9, 90.	3.3	12
33	The circular RNome of primary breast cancer. <i>Genome Research</i> , 2019, 29, 356-366.	5.5	85
34	Isocitrate dehydrogenase 1-mutated cancers are sensitive to the green tea polyphenol epigallocatechin-3-gallate. <i>Cancer & Metabolism</i> , 2019, 7, 4.	5.0	18
35	Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. <i>European Journal of Cancer</i> , 2019, 114, 128-136.	2.8	8
36	Testicular Adrenal Rest Tumors: Current Insights on Prevalence, Characteristics, Origin, and Treatment. <i>Endocrine Reviews</i> , 2019, 40, 973-987.	20.1	92

#	ARTICLE	IF	CITATIONS
37	Polyomavirus T Antigen Induces APOBEC3B Expression Using an LXCXE-Dependent and TP53-Independent Mechanism. <i>MBio</i> , 2019, 10, .	4.1	35
38	BRAFV600E Inhibitor Radiosensitizes Thyroid Cancer Letter. <i>Clinical Cancer Research</i> , 2019, 25, 6556-6556.	7.0	0
39	ACLY (ATP Citrate Lyase) Mediates Radioresistance in Head and Neck Squamous Cell Carcinomas and is a Novel Predictive Radiotherapy Biomarker. <i>Cancers</i> , 2019, 11, 1971.	3.7	21
40	Interferon-Stimulated Genes Are Involved in Cross-resistance to Radiotherapy in Tamoxifen-Resistant Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 3397-3408.	7.0	68
41	Gonadal function in adult male patients with congenital adrenal hyperplasia. <i>European Journal of Endocrinology</i> , 2018, 178, 285-294.	3.7	57
42	Mutational mechanisms of amplifications revealed by analysis of clustered rearrangements in breast cancers. <i>Annals of Oncology</i> , 2018, 29, 2223-2231.	1.2	26
43	Targeting glucose and glutamine metabolism combined with radiation therapy in non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 126, 32-40.	2.0	33
44	Predicting and Understanding Cancer Response to Treatment. <i>Disease Markers</i> , 2018, 2018, 1-2.	1.3	2
45	Imageable Biomarkers for Radiotherapy Response. <i>Progress in Tumor Research</i> , 2018, , 11-24.	0.1	0
46	HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. <i>Nature Medicine</i> , 2017, 23, 517-525.	30.7	769
47	Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. <i>Nature</i> , 2017, 543, 714-718.	27.8	229
48	Radiation oncology enters the era of individualised medicine. <i>Lancet Oncology</i> , The, 2017, 18, 159-160.	10.7	10
49	GATA transcription factors in testicular adrenal rest tumours. <i>Endocrine Connections</i> , 2017, 6, 866-875.	1.9	14
50	SP-013: Update on the ARCON study. <i>Radiotherapy and Oncology</i> , 2017, 122, 10-11.	0.6	0
51	Selective MET Kinase Inhibition in MET-Dependent Glioma Models Alters Gene Expression and Induces Tumor Plasticity. <i>Molecular Cancer Research</i> , 2017, 15, 1587-1597.	3.4	12
52	Collective invasion in ductal and lobular breast cancer associates with distant metastasis. <i>Clinical and Experimental Metastasis</i> , 2017, 34, 421-429.	3.3	66
53	Staining Against Phospho-H2AX (γ -H2AX) as a Marker for DNA Damage and Genomic Instability in Cancer Tissues and Cells. <i>Advances in Experimental Medicine and Biology</i> , 2016, 899, 1-10.	1.6	55
54	Roles and Regulation of Epithelial Splicing Regulatory Proteins 1 and 2 in Epithelial-Mesenchymal Transition. <i>International Review of Cell and Molecular Biology</i> , 2016, 327, 163-194.	3.2	33

#	ARTICLE	IF	CITATIONS
55	Engineered microparticles delivering oxygen to enhance radiotherapy efficacy. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E8009-E8009.	7.1	2
56	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature, 2016, 534, 47-54.	27.8	1,760
57	Quality-of-life after radiotherapy for advanced laryngeal cancer: Results of a phase III trial of the Dutch Head and Neck Society. Radiotherapy and Oncology, 2016, 119, 213-220.	0.6	19
58	Prognostic significance of nuclear expression of UMP-CMP kinase in triple negative breast cancer patients. Scientific Reports, 2016, 6, 32027.	3.3	19
59	The topography of mutational processes in breast cancer genomes. Nature Communications, 2016, 7, 11383.	12.8	235
60	Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. Nature Communications, 2016, 7, 12910.	12.8	119
61	The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Science Advances, 2016, 2, e1601737.	10.3	175
62	Interaction between hypoxia, AKT and HIF-1 signaling in HNSCC and NSCLC: implications for future treatment strategies. Future Science OA, 2016, 2, FSO84.	1.9	25
63	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
64	Targeted MS Assay Predicting Tamoxifen Resistance in Estrogen-Receptor-Positive Breast Cancer Tissues and Sera. Journal of Proteome Research, 2016, 15, 1230-1242.	3.7	21
65	4â€protein signature predicting tamoxifen treatment outcome in recurrent breast cancer. Molecular Oncology, 2016, 10, 24-39.	4.6	31
66	Effectiveness and toxicity of hypofractionated highâ€dose intensityâ€modulated radiotherapy versus 2â€ and 3â€dimensional radiotherapy in incurable head and neck cancer. Head and Neck, 2016, 38, E1264-70.	2.0	10
67	Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer. Oncotarget, 2016, 7, 3098-3110.	1.8	26
68	Abstract S4-07: Tamoxifen resistance driven by the DNA cytosine deaminase APOBEC3B in recurrent estrogen receptor positive breast cancer. Cancer Research, 2016, 76, S4-07-S4-07.	0.9	1
69	International biobanks: do or do not?. Future Science OA, 2015, 1, FSO75.	1.9	0
70	Hypoxic regulation of the PERK/ATF4/LAMP3â€arm of the unfolded protein response in head and neck squamous cell carcinoma. Head and Neck, 2015, 37, 896-905.	2.0	28
71	From eels to the importance of cancer biobanks. Future Science OA, 2015, 1, FSO65.	1.9	1
72	Poor prognosis of constitutive Î³-H2AX expressing triple-negative breast cancers is associated with telomere length. Biomarkers in Medicine, 2015, 9, 383-390.	1.4	17

#	ARTICLE	IF	CITATIONS
73	Molecular Characterization of Testicular Adrenal Rest Tumors in Congenital Adrenal Hyperplasia: Lesions With Both Adrenocortical and Leydig Cell Features. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E524-E530.	3.6	59
74	Biology of Hypoxia. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 101-109.	4.6	121
75	Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. <i>Genome Research</i> , 2015, 25, 814-824.	5.5	69
76	The mechanical microenvironment in cancer: How physics affects tumours. <i>Seminars in Cancer Biology</i> , 2015, 35, 62-70.	9.6	107
77	Adrenal Steroid Metabolites Accumulating in Congenital Adrenal Hyperplasia Lead to Transactivation of the Glucocorticoid Receptor. <i>Endocrinology</i> , 2015, 156, 3504-3510.	2.8	32
78	β -H2AX Foci in Peripheral Blood Lymphocytes to Quantify Radiation-Induced DNA Damage After ^{177}Lu -DOTA-Octreotate Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2015, 56, 501-502.	5.0	5
79	Improved metastasis-free survival in nonadjuvantly treated postmenopausal breast cancer patients with chemokine receptor 5 del32 frameshift mutations. <i>International Journal of Cancer</i> , 2015, 136, 91-97.	5.1	16
80	Therapeutic targeting of autophagy in cancer. Part I: Molecular pathways controlling autophagy. <i>Seminars in Cancer Biology</i> , 2015, 31, 89-98.	9.6	47
81	Therapeutic targeting of autophagy in cancer. Part II: Pharmacological modulation of treatment-induced autophagy. <i>Seminars in Cancer Biology</i> , 2015, 31, 99-105.	9.6	69
82	Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT. <i>Journal of Clinical Investigation</i> , 2015, 125, 2385-2398.	8.2	111
83	Abstract LB-118: High APOBEC3B mRNA levels in estrogen receptor-positive primary tumors predict short time to progression for hormone-naïve breast cancer patients treated with 1st line tamoxifen. , 2015, , .		0
84	Tumor Microenvironmental Changes Induced by the Sulfamate Carbonic Anhydrase IX Inhibitor S4 in a Laryngeal Tumor Model. <i>PLoS ONE</i> , 2014, 9, e108068.	2.5	18
85	HIF-1 α -independent hypoxia-induced rapid PTK6 stabilization is associated with increased motility and invasion. <i>Cancer Biology and Therapy</i> , 2014, 15, 1350-1357.	3.4	27
86	Processed pseudogenes acquired somatically during cancer development. <i>Nature Communications</i> , 2014, 5, 3644.	12.8	86
87	Comparative Proteome Analysis Revealing an 11-Protein Signature for Aggressive Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt376.	6.3	77
88	Ferritin Heavy Chain in Triple Negative Breast Cancer: A Favorable Prognostic Marker that Relates to a Cluster of Differentiation 8 Positive (CD8+) Effector T-cell Response. <i>Molecular and Cellular Proteomics</i> , 2014, 13, 1814-1827.	3.8	44
89	Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model. <i>Contrast Media and Molecular Imaging</i> , 2014, 9, 237-245.	0.8	24
90	Glucose Metabolism in NSCLC Is Histology-Specific and Diverges the Prognostic Potential of ^{18}F FDG-PET for Adenocarcinoma and Squamous Cell Carcinoma. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1485-1493.	1.1	107

#	ARTICLE	IF	CITATIONS
91	The Effect of Carbogen Breathing and Nicotinamide Added to Standard (Chemo)Radiation Treatment of Advanced Cervical Cancer in Indonesia. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1628-1635.	2.5	8
92	Quantification of Patient-Specific Assay Interference in Different Formats of Enzyme-Linked Immunoassays for Therapeutic Monoclonal Antibodies. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 765-770.	2.0	8
93	Improved Recurrence-Free Survival with ARCON for Anemic Patients with Laryngeal Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1345-1354.	7.0	43
94	Computed tomography-based tumour volume as a predictor of outcome in laryngeal cancer: Results of the phase 3 ARCON trial. <i>European Journal of Cancer</i> , 2014, 50, 1112-1119.	2.8	21
95	Improving chemoradiation efficacy by PI3-K/AKT inhibition. <i>Cancer Treatment Reviews</i> , 2014, 40, 1182-1191.	7.7	39
96	Evaluation of the ability of adjuvant tamoxifen benefit gene signatures to predict outcome of hormone-naïve estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting. <i>Molecular Oncology</i> , 2014, 8, 1679-1689.	4.6	18
97	Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. <i>Science</i> , 2014, 345, 1251343.	12.6	348
98	The unfolded protein response as a target for cancer therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 277-284.	7.4	60
99	LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy. <i>Endocrine-Related Cancer</i> , 2014, 21, 101-112.	3.1	82
100	Effect of hypoxia on the expression of β -crystallin in head and neck squamous cell carcinoma. <i>BMC Cancer</i> , 2014, 14, 252.	2.6	17
101	Abstract 1611: 4-protein signature predicts outcome to tamoxifen treatment in estrogen receptor positive recurrent breast cancer. , 2014, , .		0
102	Hypoxia stimulates migration of breast cancer cells via the PERK/ATF4/LAMP3-arm of the unfolded protein response. <i>Breast Cancer Research</i> , 2013, 15, R2.	5.0	194
103	β -crystallin stimulates VEGF secretion and tumor cell migration and correlates with enhanced distant metastasis in head and neck squamous cell carcinoma. <i>BMC Cancer</i> , 2013, 13, 128.	2.6	30
104	Interaction of EGFR with the tumour microenvironment: Implications for radiation treatment. <i>Radiotherapy and Oncology</i> , 2013, 108, 17-23.	0.6	42
105	Signatures of mutational processes in human cancer. <i>Nature</i> , 2013, 500, 415-421.	27.8	8,060
106	Diffusion-weighted MR imaging in liver metastases of colorectal cancer: reproducibility and biological validation. <i>European Radiology</i> , 2013, 23, 748-756.	4.5	65
107	Dasatinib Inhibits DNA Repair after Radiotherapy Specifically in pSFK-Expressing Tumor Areas in Head and Neck Xenograft Tumors. <i>Translational Oncology</i> , 2013, 6, 413-419.	3.7	9
108	Hypoxia, metabolism, and growth factor signaling in head and neck squamous cell carcinoma: Correlation between primary and xenograft tumors. <i>Head and Neck</i> , 2013, 36, n/a-n/a.	2.0	9

#	ARTICLE	IF	CITATIONS
109	A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 4879-4888.	7.0	214
110	Breast cancer size estimation with MRI in BRCA mutation carriers and other high risk patients. <i>European Journal of Radiology</i> , 2013, 82, 1416-1422.	2.6	18
111	Pathology-based validation of FDG PET segmentation tools for volume assessment of lymph node metastases from head and neck cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 40, 1828-1835.	6.4	26
112	Generation of multicellular tumor spheroids of breast cancer cells: How to go three-dimensional. <i>Analytical Biochemistry</i> , 2013, 437, 17-19.	2.4	57
113	The PERK/ATF4/LAMP3-arm of the unfolded protein response affects radioresistance by interfering with the DNA damage response. <i>Radiotherapy and Oncology</i> , 2013, 108, 415-421.	0.6	83
114	Epidermal growth factor receptor expression in laryngeal cancer predicts the effect of hypoxia modification as an additive to accelerated radiotherapy in a randomised controlled trial. <i>European Journal of Cancer</i> , 2013, 49, 3202-3209.	2.8	27
115	EGFR overexpressing cells and tumors are dependent on autophagy for growth and survival. <i>Radiotherapy and Oncology</i> , 2013, 108, 479-483.	0.6	38
116	Predictive value of hypoxia, proliferation and tyrosine kinase receptors for EGFR-inhibition and radiotherapy sensitivity in head and neck cancer models. <i>Radiotherapy and Oncology</i> , 2013, 106, 383-389.	0.6	36
117	High NOTCH activity induces radiation resistance in non small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2013, 108, 440-445.	0.6	60
118	Low Phosphorylated AKT Expression in Laryngeal Cancer: Indications for a Higher Metastatic Risk. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 349-355.	0.8	6
119	Comparability versus statistical correctness. <i>European Journal of Radiology</i> , 2013, 82, e908.	2.6	1
120	Hypofractionation vs Conventional Radiation Therapy for Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Matched-Cohort Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 315-320.	0.8	92
121	Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach. <i>Investigational New Drugs</i> , 2013, 31, 881-890.	2.6	7
122	¹⁸ F-FLT PET During Radiotherapy or Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma Is an Early Predictor of Outcome. <i>Journal of Nuclear Medicine</i> , 2013, 54, 532-540.	5.0	111
123	Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 39-49.	2.5	49
124	Hypoxic Activation of the PERK/eIF2 β Arm of the Unfolded Protein Response Promotes Metastasis through Induction of LAMP3. <i>Clinical Cancer Research</i> , 2013, 19, 6126-6137.	7.0	105
125	EGFR-Inhibition Enhances Apoptosis in Irradiated Human Head and Neck Xenograft Tumors Independent of Effects on DNA Repair. <i>Radiation Research</i> , 2013, 180, 414.	1.5	8
126	Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines. <i>Molecular Cancer</i> , 2013, 12, 133.	19.2	25

#	ARTICLE	IF	CITATIONS
127	Hypoxia Regulation of Phosphokinases and the Prognostic Value of pAKT in Breast Cancer. International Journal of Biological Markers, 2013, 28, 151-160.	1.8	11
128	Î±B-Crystallin Expression is Correlated with Phospho-ERK1/2 Expression in Human Breast Cancer. International Journal of Biological Markers, 2013, 28, 365-370.	1.8	5
129	Downregulation of Serine Protease HTRA1 Is Associated with Poor Survival in Breast Cancer. PLoS ONE, 2013, 8, e60359.	2.5	28
130	Independent and functional validation of a multi-tumour-type proliferation signature. British Journal of Cancer, 2012, 107, 508-515.	6.4	17
131	Targeting Hypoxia, HIF-1, and Tumor Glucose Metabolism to Improve Radiotherapy Efficacy. Clinical Cancer Research, 2012, 18, 5585-5594.	7.0	374
132	Expression of the BRCA1 complex member BRE predicts disease free survival in breast cancer. Breast Cancer Research and Treatment, 2012, 135, 125-133.	2.5	14
133	High Occurrence of Aberrant Lymph Node Spread on Magnetic Resonance Lymphography in Prostate Cancer Patients With a Biochemical Recurrence After Radical Prostatectomy. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1405-1410.	0.8	35
134	Magnetic Resonance Lymphography Findings in Patients With Biochemical Recurrence After Prostatectomy and the Relation With the Stephenson Nomogram. International Journal of Radiation Oncology Biology Physics, 2012, 84, 1186-1191.	0.8	8
135	TRPM7 Is Required for Breast Tumor Cell Metastasis. Cancer Research, 2012, 72, 4250-4261.	0.9	186
136	Accelerated Radiotherapy With Carbogen and Nicotinamide for Laryngeal Cancer: Results of a Phase III Randomized Trial. Journal of Clinical Oncology, 2012, 30, 1777-1783.	1.6	222
137	Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck. BMC Cancer, 2012, 12, 463.	2.6	58
138	Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas: Spatial distribution and prognostic value of GLUT1 and MCT4. Lung Cancer, 2012, 76, 316-323.	2.0	99
139	Treatment outcome and toxicity of intensity-modulated (chemo) radiotherapy in stage III non-small cell lung cancer patients. Radiation Oncology, 2012, 7, 150.	2.7	33
140	Regulation of TRIB3 mRNA and Protein in Breast Cancer. PLoS ONE, 2012, 7, e49439.	2.5	28
141	Tumor hypoxia as a mechanism of resistance to bevacizumab in a murine model.. Journal of Clinical Oncology, 2012, 30, e13111-e13111.	1.6	1
142	The <i>CYP2C19*2</i> genotype predicts tamoxifen treatment outcome in advanced breast cancer patients. Pharmacogenomics, 2011, 12, 1137-1146.	1.3	44
143	PP 49 Prognostic value of GLUT1 and MCT4 expression in adeno- and squamous cell non-small cell lung cancer. European Journal of Cancer, 2011, 47, S24.	2.8	0
144	PP 48 TRIB3: a prognostic factor and involved in hypoxia sensitivity in breast cancer patients. European Journal of Cancer, 2011, 47, S33.	2.8	0

#	ARTICLE	IF	CITATIONS
145	Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response. Breast Cancer Research, 2011, 13, R82.	5.0	74
146	TRIB3 protein denotes a good prognosis in breast cancer patients and is associated with hypoxia sensitivity. Radiotherapy and Oncology, 2011, 101, 198-202.	0.6	37
147	Expression of E-cadherin and vimentin correlates with metastasis formation in head and neck squamous cell carcinoma patients. Radiotherapy and Oncology, 2011, 99, 344-348.	0.6	161
148	Spatial relationship of phosphorylated epidermal growth factor receptor and activated AKT in head and neck squamous cell carcinoma. Radiotherapy and Oncology, 2011, 101, 165-170.	0.6	24
149	Constitutive expression of γ -H2AX has prognostic relevance in triple negative breast cancer. Radiotherapy and Oncology, 2011, 101, 39-45.	0.6	74
150	Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1773-1783.	2.5	9
151	Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1449-1458.	6.4	70
152	Hypoxic regulation and prognostic value of LAMP3 expression in breast cancer. Cancer, 2011, 117, 3670-3681.	4.1	57
153	Overexpression of the natural antisense hypoxia-inducible factor-1 β transcript is associated with malignant pheochromocytoma/paraganglioma. Endocrine-Related Cancer, 2011, 18, 323-331.	3.1	39
154	Cathepsins B, L and cystatin C in cyst fluid of ovarian tumors. Journal of Cancer Research and Clinical Oncology, 2010, 136, 771-778.	2.5	26
155	Tamoxifen sensitivity and estrogen receptor mRNA levels. Breast Cancer Research and Treatment, 2010, 121, 793-794.	2.5	0
156	Crosstalk and DC-SCRIPT: Expanding nuclear receptor modulation. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1806, 193-199.	7.4	11
157	Metalloproteinases and their regulators in colorectal cancer. Journal of Surgical Oncology, 2010, 101, 259-269.	1.7	29
158	Mammaglobin RT-PCR for breast cancer metastasis detection in sentinel lymph nodes. Cancer Science, 2010, 101, 2501-2501.	3.9	1
159	The balance between extracellular cathepsins and cystatin C is of importance for ovarian cancer. European Journal of Clinical Investigation, 2010, 40, 591-599.	3.4	28
160	18S is an appropriate housekeeping gene for in vitro hypoxia experiments. British Journal of Cancer, 2010, 103, 590-590.	6.4	19
161	DC-SCRIPT: Nuclear Receptor Modulation and Prognostic Significance in Primary Breast Cancer. Journal of the National Cancer Institute, 2010, 102, 54-68.	6.3	22
162	Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study. Breast Cancer Research, 2010, 12, R103.	5.0	20

#	ARTICLE	IF	CITATIONS
163	Expression of carbonic anhydrase IX suggests poor response to therapy in rectal cancer. <i>British Journal of Cancer</i> , 2009, 101, 372-372.	6.4	3
164	Genomic actions of estrogen receptor β : what are the targets and how are they regulated?. <i>Endocrine-Related Cancer</i> , 2009, 16, 1073-1089.	3.1	128
165	Serum vascular endothelial growth factor: a prognostic factor in cervical cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 283-290.	2.5	26
166	The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 303-309.	2.5	134
167	ChIP-Seq of ER β and RNA polymerase II defines genes differentially responding to ligands. <i>EMBO Journal</i> , 2009, 28, 1418-1428.	7.8	377
168	Harmonisation of multi-centre real-time reverse-transcribed PCR results of a candidate prognostic marker in breast cancer: An EU-FP6 supported study of members of the EORTC "PathoBiology Group". <i>European Journal of Cancer</i> , 2009, 45, 74-81.	2.8	2
169	Methylated genes as new cancer biomarkers. <i>European Journal of Cancer</i> , 2009, 45, 335-346.	2.8	92
170	Occurrence of postmenopausal-like acidic follicle-stimulating hormone (FSH) isoforms precedes the rise of FSH before menopause. <i>Fertility and Sterility</i> , 2009, 92, 613-619.	1.0	5
171	Angiogenesis, hypoxia and VEGF expression during tumour growth in a human xenograft tumour model. <i>Microvascular Research</i> , 2009, 77, 96-103.	2.5	84
172	Prognostic value of CA 125 in ovarian cyst fluid of patients with epithelial ovarian cancer. <i>Oncology Reports</i> , 2009, 23, .	2.6	3
173	Rho GDP dissociation inhibitor β expression correlates with the outcome of CMF treatment in invasive ductal breast cancer. <i>International Journal of Oncology</i> , 2009, 36, .	3.3	2
174	Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues. <i>BJU International</i> , 2008, 102, 177-182.	2.5	19
175	Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients. <i>BMC Cancer</i> , 2008, 8, 389.	2.6	22
176	Molecular aspects of tumour hypoxia. <i>Molecular Oncology</i> , 2008, 2, 41-53.	4.6	126
177	Cox-2 is a target gene of Rho GDP dissociation inhibitor beta in breast cancer cells. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 82.	2.2	0
178	Matrix metalloproteinase-8 is a regulator of the clinical aggressiveness of mammary tumours. <i>Breast Cancer Research</i> , 2008, 10, .	5.0	0
179	Distinct Functions of Natural ADAM-15 Cytoplasmic Domain Variants in Human Mammary Carcinoma. <i>Molecular Cancer Research</i> , 2008, 6, 383-394.	3.4	60
180	Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: Comparison to antigen quantification by ELISA. <i>International Journal of Molecular Medicine</i> , 2008, , .	4.0	11

#	ARTICLE	IF	CITATIONS
181	Matrix Metalloproteinase-8 Functions as a Metastasis Suppressor through Modulation of Tumor Cell Adhesion and Invasion. <i>Cancer Research</i> , 2008, 68, 2755-2763.	0.9	172
182	Carbonic anhydrase IX expression is more predictive than prognostic in breast cancer. <i>British Journal of Cancer</i> , 2007, 96, 1309-1309.	6.4	7
183	Testicular Tumors in Patients with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency Show Functional Features of Adrenocortical Tissue. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 3674-3680.	3.6	109
184	Re: p27Kip1 and Cyclin E Expression and Breast Cancer Survival After Treatment With Adjuvant Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2007, 99, 738-738.	6.3	5
185	<i>Cyclooxygenase-2</i> Is a Target Gene of Rho GDP Dissociation Inhibitor $\hat{1}^2$ in Breast Cancer Cells. <i>Cancer Research</i> , 2007, 67, 10694-10702.	0.9	29
186	Early identification of treatment resistance in GTN. <i>Lancet Oncology</i> , The, 2007, 8, 866-867.	10.7	1
187	Identifying estrogen receptor target genes. <i>Molecular Oncology</i> , 2007, 1, 138-143.	4.6	61
188	Is survivin expression nevertheless related to disease outcome in breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2007, 103, 109-109.	2.5	3
189	Correlation of reversion-inducing cysteine-rich protein with kazal motifs (RECK) and extracellular matrix metalloproteinase inducer (EMMPRIN), with MMP-2, MMP-9, and survival in colorectal cancer. <i>Cancer Letters</i> , 2006, 237, 289-297.	7.2	55
190	High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006, 98, 223-230.	2.5	32
191	ADAMTS8 and ADAMTS15 expression predicts survival in human breast carcinoma. <i>International Journal of Cancer</i> , 2006, 118, 1241-1247.	5.1	82
192	Molecular profiling of platinum resistant ovarian cancer. <i>International Journal of Cancer</i> , 2006, 118, 1963-1971.	5.1	139
193	Multicenter Validation of a Gene Expression-Based Prognostic Signature in Lymph Node-Negative Primary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 1665-1671.	1.6	328
194	Parathyroid Hormone-related Protein Regulates Tumor-relevant Genes in Breast Cancer Cells*. <i>Journal of Biological Chemistry</i> , 2006, 281, 14563-14572.	3.4	36
195	Quantitative Reverse Transcription-PCR Assay for Detection of mRNA Encoding Full-Length Human Tissue Kallikrein 7: Prognostic Relevance of KLK7 mRNA Expression in Breast Cancer 3. <i>Clinical Chemistry</i> , 2006, 52, 1070-1079.	3.2	20
196	Do the Survivin (BIRC5) Splice Variants Modulate or Add to the Prognostic Value of Total Survivin in Breast Cancer?. <i>Clinical Chemistry</i> , 2006, 52, 1693-1700.	3.2	51
197	Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. <i>Laboratory Investigation</i> , 2005, 85, 154-159.	3.7	482
198	Concerns about Mammaglobin Assays. <i>Clinical Chemistry</i> , 2005, 51, 474-475.	3.2	0

#	ARTICLE	IF	CITATIONS
199	Mammaglobin as Molecular Marker of Breast Cancer (Micro)Metastases. <i>Clinical Cancer Research</i> , 2005, 11, 7043-7044.	7.0	5
200	Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer. <i>European Journal of Cancer</i> , 2005, 41, 2760-2768.	2.8	44
201	The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) independently predicts response to first-line endocrine therapy in advanced breast cancer. <i>Thrombosis and Haemostasis</i> , 2004, 91, 514-521.	3.4	12
202	Role of Hexosamines in Insulin Resistance and Nutrient Sensing in Human Adipose and Muscle Tissue. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5132-5137.	3.6	10
203	Expression and localisation of the new metalloproteinase inhibitor RECK (reversion inducing) Tj ETQq1 1 0.784314 rgBT /Overlock 10 arthritis. <i>Annals of the Rheumatic Diseases</i> , 2004, 64, 368-374.	0.9	28
204	Development of an ELISA for Measurement of BCAR1 Protein in Human Breast Cancer Tissue. <i>Clinical Chemistry</i> , 2004, 50, 1356-1363.	3.2	12
205	Predictive Impact of Urokinase-Type Plasminogen Activator. <i>Cancer Research</i> , 2004, 64, 659-664.	0.9	41
206	The Prognostic Value of BCAR1 in Patients with Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6194-6202.	7.0	51
207	Mammaglobin Is Associated With Low-Grade, Steroid Receptor-Positive Breast Tumors From Postmenopausal Patients, and Has Independent Prognostic Value for Relapse-Free Survival Time. <i>Journal of Clinical Oncology</i> , 2004, 22, 691-698.	1.6	75
208	Survivin Is an Independent Prognostic Marker for Risk Stratification of Breast Cancer Patients. <i>Clinical Chemistry</i> , 2004, 50, 1986-1993.	3.2	121
209	Application of a Newly Developed ELISA for BCAR1 Protein for Prediction of Clinical Benefit of Tamoxifen Therapy in Patients with Advanced Breast Cancer. <i>Clinical Chemistry</i> , 2004, 50, 1445-1447.	3.2	9
210	Effects of PhD examination stress on allopregnanolone and cortisol plasma levels and peripheral benzodiazepine receptor density. <i>Psychoneuroendocrinology</i> , 2004, 29, 1341-1344.	2.7	93
211	Hexosamines Are Unlikely to Function as a Nutrient-Sensor in 3T3-L1 Adipocytes: A Comparison of UDP-Hexosamine Levels after Increased Glucose Flux and Glucosamine Treatment. <i>Endocrine</i> , 2004, 23, 17-24.	2.2	14
212	Elevated levels of vascular endothelial growth factor in serum of patients with D+ HUS. <i>Pediatric Nephrology</i> , 2004, 19, 754-760.	1.7	19
213	Tissue inhibitors of metalloproteinase expression in human breast cancer: TIMP-3 is associated with adjuvant endocrine therapy success. <i>Journal of Pathology</i> , 2004, 202, 395-402.	4.5	44
214	Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma. <i>Cancer</i> , 2004, 101, 486-494.	4.1	35
215	Regulation of GLUT1-mediated glucose uptake by PKC β interactions in 3T3-L1 adipocytes. <i>Biochemical Journal</i> , 2004, 384, 349-355.	3.7	16
216	Exploring Levels of Hexosamine Biosynthesis Pathway Intermediates and Protein Kinase C Isoforms in Muscle and Fat Tissue of Zucker Diabetic Fatty Rats. <i>Endocrine</i> , 2003, 20, 247-252.	2.2	10

#	ARTICLE	IF	CITATIONS
217	EIAF Expression Levels are not Associated with Prognosis in Human Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2003, 79, 129-131.	2.5	7
218	Matrix metalloproteinase inhibitor reversion-inducing cysteine-rich protein with Kazal motifs. <i>Cancer</i> , 2003, 97, 2710-2715.	4.1	92
219	Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma. <i>Cancer</i> , 2003, 98, 2125-2132.	4.1	75
220	Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer. <i>Oncogene</i> , 2003, 22, 4898-4904.	5.9	79
221	Phlorizin treatment prevents the decrease in plasma insulin levels but not the progressive histopathological changes in the pancreatic islets during aging of Zucker diabetic fatty rats. <i>Journal of Endocrinological Investigation</i> , 2003, 26, 508-515.	3.3	18
222	Inhibition of Protein Kinase C ^β Increases Glucose Uptake in 3T3-L1 Adipocytes through Elevated Expression of Glucose Transporter 1 at the Plasma Membrane. <i>Molecular Endocrinology</i> , 2003, 17, 1230-1239.	3.7	16
223	Molecular Beacon Reverse Transcription-PCR of Human Chorionic Gonadotropin-β ²⁻³ , -5, and -8 mRNAs Has Prognostic Value in Breast Cancer. <i>Clinical Chemistry</i> , 2003, 49, 1074-1080.	3.2	24
224	Quantitative detection of peripheral thyroglobulin mRNA has limited clinical value in the follow-up of thyroid cancer patients. <i>Annals of Clinical Biochemistry</i> , 2003, 40, 94-99.	1.6	33
225	Carbonic anhydrase-9 expression levels and prognosis in human breast cancer: association with treatment outcome. <i>British Journal of Cancer</i> , 2003, 89, 271-276.	6.4	102
226	Screening for Interference in Immunoassays. <i>Clinical Chemistry</i> , 2003, 49, 1708-1709.	3.2	14
227	Vascular endothelial growth factor independently predicts the efficacy of postoperative radiotherapy in node-negative breast cancer patients. <i>Clinical Cancer Research</i> , 2003, 9, 6363-70.	7.0	32
228	Serial Plasma Concentrations of Atrial Natriuretic Peptide, Plasma Renin Activity, Aldosterone, and Antidiuretic Hormone in Neonates on Extracorporeal Membrane Oxygenation. <i>ASAIO Journal</i> , 2002, 48, 26-33.	1.6	17
229	Muscle Uridine Diphosphate-Hexosamines Do Not Decrease Despite Correction of Hyperglycemia-Induced Insulin Resistance in Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 5179-5184.	3.6	17
230	Analysis of expression of chorionic gonadotrophin transcripts in prostate cancer by quantitative Taqman and a modified molecular beacon RT-PCR. <i>Journal of Endocrinology</i> , 2002, 172, 489-495.	2.6	18
231	Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. <i>Oncogene</i> , 2002, 21, 8506-8509.	5.9	148
232	Dietary fatty acid composition during pregnancy and lactation in the rat programs growth and glucose metabolism in the offspring. <i>Diabetologia</i> , 2002, 45, 1397-1403.	6.3	108
233	Reduced adrenal response to bacterial lipopolysaccharide in interleukin-6-deficient mice. <i>Journal of Endocrinological Investigation</i> , 2001, 24, 786-795.	3.3	17
234	Assay for Hexosamine Pathway Intermediates (Uridine Diphosphate-N-Acetyl Amino Sugars) in Small Samples of Human Muscle Tissue. <i>Clinical Chemistry</i> , 2001, 47, 944-946.	3.2	14

#	ARTICLE	IF	CITATIONS
235	Short-Term Glucosamine Infusion Does Not Affect Insulin Sensitivity in Humans1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2099-2103.	3.6	54
236	Implications of Progesterone Metabolism in MA-10 Cells for Accurate Measurement of the Rate of Steroidogenesis. Endocrinology, 2001, 142, 5236-5242.	2.8	2
237	Short-Term Glucosamine Infusion Does Not Affect Insulin Sensitivity in Humans. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2099-2103.	3.6	44
238	Partial sequencing and tissue distribution of the canine isoforms of steroid 5 β -Reductase type I and type II. Prostate, 2000, 44, 233-239.	2.3	9
239	A prospective randomized trial evaluating tissue effects of finasteride therapy in benign prostatic hyperplasia. Prostate Cancer and Prostatic Diseases, 1999, 2, 277-281.	3.9	15
240	SELECTIVITY OF FINASTERIDE AS AN IN VIVO INHIBITOR OF 5 alpha-REDUCTASE ISOZYME ENZYMATIC ACTIVITY IN THE HUMAN PROSTATE. Journal of Urology, 1999, 161, 332-337.	0.4	73
241	Plasma Concentrations of Atrial Natriuretic Peptide (ANP), Plasma Renin Activity (PRA), Aldosterone (Aldo) and Arginine-Vasopressin (AVP) in Neonates on Extracorporeal Membrane Oxygenation (ECMO). Pediatric Research, 1999, 45, 224A-224A.	2.3	0
242	Identification and partial characterization of two steroid 5 β -reductase isozymes in the canine prostate. , 1998, 34, 222-230.		12
243	Kinetic analysis of rat steroid 5 β -reductase activity in prostate and epididymis homogenates at neutral pH: Evidence for type I activity in epididymis. Journal of Steroid Biochemistry and Molecular Biology, 1996, 57, 95-101.	2.5	8
244	3 β -Hydroxysteroid oxidoreductase activities in dihydrotestosterone degradation and back-formation in rat prostate and epididymis. Journal of Steroid Biochemistry and Molecular Biology, 1996, 58, 319-324.	2.5	16
245	Kinetic analysis of steroid 5 β -reductase activity at neutral pH in benign prostatic hyperplastic tissue: Evidence for type I isozyme activity in the human prostate. Journal of Steroid Biochemistry and Molecular Biology, 1996, 57, 103-108.	2.5	32
246	Differential subcellular distribution of rat prostatic steroid 5 β -reductase isozyme activities. European Journal of Endocrinology, 1996, 134, 386-392.	3.7	8
247	Rat steroid 5 β -reductase kinetic characteristics: Extreme pH-dependency of the type II isozyme in prostate and epididymis homogenates. Journal of Steroid Biochemistry and Molecular Biology, 1995, 54, 185-192.	2.5	13
248	Virus α -induced airway hyperresponsiveness in the guinea α pig: possible involvement of histamine and inflammatory cells. British Journal of Pharmacology, 1993, 108, 1083-1093.	5.4	22